文献速递神经免疫

种族不平等、多发性硬化及健康系统层面新型治疗算法的实施

Racial Inequities, Multiple Sclerosis, and Implementation of a Novel Treatment Algorithm at the Health System Level.
PubMed 文献 · Neurology · 2025-04-21

研究设计并实施了一种多发性硬化(MS)治疗算法,将患者残疾风险与疾病修饰疗法(DMT)匹配,并纳入健康社会决定因素和患者偏好,但不包含种族或民族。利用Kaiser Permanente南加州电子健康记录进行趋势研究,发现实施该算法后高效疗法(HET)使用增加,年复发率(ARR)显著下降,且西班牙裔、黑人和白人DMT治疗患者间的ARR差异至2023年不再具有临床显著性。

要点

  • 实施治疗算法后,西班牙裔、黑人和白人DMT治疗患者的HET使用率均大幅增加,2023年分别达89.3%、87.4%和82.9%。
  • 2011至2023年,西班牙裔、白人和黑人患者的调整后ARR分别下降90%、86%和82%。
  • 至2023年,西班牙裔、黑人和白人患者的ARR分别为35.5、19.0和18.1/1000人年,组间无临床显著差异。

核心结论

  • 实施新型健康系统干预在多发性硬化DMT治疗患者中实现了HET使用和复发率降低的显著且公平的改善。
  • 采用算法化方法增加HET使用,特别是可负担的利妥昔单抗,可减少MS结局的种族和民族差异。

研究设计与样本

  • 设计并实施了一种MS治疗算法,将患者残疾风险与适当有效的DMT匹配,并纳入健康社会决定因素和患者偏好,但不包含种族或民族。
  • 利用Kaiser Permanente南加州电子健康记录,对2009-2011年(实施前)和2012-2023年(实施期间)按种族和民族分层的DMT使用和年复发率(ARR)进行趋势研究。
  • 研究期间共识别6,119名DMT治疗的患者(978名黑人,1741名西班牙裔,3400名白人),平均年龄50.1岁,女性占75.4%。

主要发现

  • 实施前,西班牙裔DMT治疗患者的ARR(245.1/1000人年,95%CI 205.5-284.8)显著高于白人患者(156.3/1000人年,95%CI 137.8-174.7)。
  • 黑人在实施前和早期实施期间ARR高于白人,但该差异仅在2015年显著。
  • 12年实施期间,DMT治疗患者中HET使用(主要为利妥昔单抗)的增加在西班牙裔中最高,其次为黑人和白人(2023年分别为89.3%、87.4%和82.9%)。
  • 2011至2023年,年龄和性别调整后的ARR下降幅度在西班牙裔中最大(90%,95%CI 89%-91%),其次为白人(86%,95%CI 85%-87%)和黑人(82%,95%CI 80%-84%)。
  • 至2023年,组间ARR无临床显著差异(西班牙裔、黑人和白人分别为35.5、19.0和18.1/1000人年)。

临床怎么用

  • 实施算法化方法增加HET使用,尤其是可负担的利妥昔单抗,可减少MS结局的种族和民族差异。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Advances in multiple sclerosis (MS) have not translated into equitable improvements in MS treatment or outcomes among minoritized people. Our objective was to determine whether a health system intervention designed to increase use of highly efficacious treatments (HETs) was implemented equitably and led to similar improvements in MS outcomes across racial and ethnic groups. METHODS: We designed and implemented an MS treatment algorithm that aligns a person's risk of disability with appropriately efficacious disease-modifying therapies (DMTs) and incorporates social determinants of health and patient preferences that can adversely affect adherence but does not include race or ethnicity. We used Kaiser Permanente Southern California's electronic health record to conduct a trend study of DMT utilization and annual relapse rates (ARRs) stratified by race and ethnicity before (2009-2011) and during (2012-2023) implementation of the treatment algorithm. RESULTS: We identified 6,119 (978 Black, 1741 Hispanic, 3,400 White) DMT-treated patients with MS (mean age = 50.1 years, 75.4% female) during the study period. Before implementation, Hispanic DMT-treated patients had significantly higher ARRs per 1,000 person-years (PY) (245.1, 95%CI 205.5-284.8) compared with White DMT-treated patients (156.3, 95%CI 137.8-174.7). Black people had higher ARRs compared with White people before and during early implementation, but this difference was significant only in 2015. Over the 12 years of implementation, the increase in HET use (primarily rituximab) among DMT-treated patients with MS was highest among Hispanic people, followed by Black and White people (89.3%, 87.4%, and 82.9% in 2023, respectively). The corresponding decline in age-adjusted and sex-adjusted ARR (linear spline regression) was greatest among Hispanic (90%, 95% CI 89%-91%), followed by White (86%, 95% CI 85%-87%) and Black (82%, 95% CI 80%-84%) DMT-treated patients between 2011 and 2023. By 2023, no clinically significant difference in ARR between groups remained (35.5, 19.0, and 18.1 per 1,000 PY for Hispanic, Black, and White people, respectively). DISCUSSION: Implementation of our novel health system intervention led to marked and equitable improvements in HET use and relapse rate reduction among Hispanic, Black, and White DMT-treated patients with MS. This indicates that implementing an algorithmic approach to increase HET use, particularly an affordable one, rituximab, can reduce racial and ethnic disparities in MS outcomes.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Langer-Gould A, Li BH, Smith JB, et al. Racial Inequities, Multiple Sclerosis, and Implementation of a Novel Treatment Algorithm at the Health System Level. Neurology. 2025. PMID: 40258207. doi:10.1212/WNL.0000000000213607

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。